RE:RE:RE:RE:RE:RE:RE:What did we learn here?To me, it adds to the value of when this treatment may be most effective where others are not --the nut they are attempting to crack for very sick, late stage, metastatic cancers where it's reaching the point that if it spreads, there's nothing to do. No one has anything there yet.
From what they've been saying over the last year or so, once these solid tumor cancers reach the metasticizing phase, it's quick and sure death. If they can show there's a rationale for combating that aspect -- just stopping the spread and hopefully keeping the main cancer at bay, it achieves quite a bit as a novel therapy.
Our Univ Gothemburg friends are focusing on the sortilin/stem cell affinity for their approach to treating TNBC, so they are also tangentially involved with sortilin/CSC, but in a different way.
All of this surrounding in vitro evidence is great, bodes well, and may be why such top institutions are working with them. Let's just hope it does it's thing in some of the 1b patients. Since we already knew this data from the poster earlier in the year, I'm not changing anything on the chart --also, not in humans at this point. But we're getting close!
jfm1330 wrote: Tumor growth inhibition, in other words, slowing down growth speed, is not even stable disease on an animal model, so not close to tumor shrinkage. I understand that these CSCs are very resistant, but this is relatively minor result. It adds a thin layer of knowledge to the whole thing on animal models and genetically homogenous tumors, but it really does not mean much for real human patients.
For me the main thing I take from this PR, is that they were willing to publish it at this stage. Maybe I don't understand how it works in reality, but it seems to me that I would not publish positive results on animals if I would not already have some efficacy data in the phase Ib. If they have these efficacy signs in phase Ib, then it makes a lot of sense to publish this press release today. It's a way to send a signal that everything is on track. That's the way I see it, but again, it's only me.